Roman Butler Fullerton & Co’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-7,331
Closed -$1.18M 208
2023
Q3
$1.18M Sell
7,331
-829
-10% -$146K 0.55% 51
2023
Q2
$1.51M Hold
8,160
0.69% 38
2023
Q1
$971K Buy
+8,160
New +$959K 0.48% 66
2022
Q1
Sell
-3,975
Closed -$296K 194
2021
Q4
$296K Buy
+3,975
New +$236K 0.13% 152

Other funds holding ACLS

Roman Butler Fullerton & Co's ACLS Position: Q4 2023 in Review

Roman Butler Fullerton & Co sold out of Axcelis (ACLS) in Q4 2023, closing a stake of 7,331 shares — an estimated $1.18M sold.

Roman Butler Fullerton & Co first reported a position in ACLS in Q4 2021 and held it in 4 quarters. The position peaked at $1.51M in Q2 2023. 420 funds tracked by Wall St. Rank hold ACLS as of Q4 2023.

  • Roman Butler Fullerton & Co reported no remaining Axcelis position as of Q4 2023 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 7,331 Axcelis shares in Q4 2023, an estimated $1.18M.
  • Roman Butler Fullerton & Co first reported a position in Axcelis in Q4 2021 and held it in 4 quarters.
  • Roman Butler Fullerton & Co's Axcelis position peaked at $1.51M in Q2 2023.
  • 420 funds tracked by Wall St. Rank held Axcelis as of Q4 2023.

Based on Roman Butler Fullerton & Co's 13F filing for Q4 2023, filed 31 Jan 2024.